参考文献
B
Baba M, 2005
Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.
TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005 Nov;49(11):4584-91.
Bangsberg DR, 2006
Bangsberg DR.
Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006 Oct 1;43(7):939-41. Epub 2006 Aug 23.
Baxter JD, 2000
Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000 Jun 16;14(9):F83-93.
Boone LR, 2006
Boone LR.
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35.
Botta M, 2002
Botta M, Corelli F, Manetti F, Tafi A.
Molecular modeling as a powerful technique for understanding small-large molecules interactions. Farmaco. 2002 Feb;57(2):153-65.
C
Cahn P, 2008
Cahn P, Rolon M, Cassetti I, Shiveley L, Holdich T, Sawyer J.
Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.
Carlsson J, 2008
Carlsson J, Boukharta L, Aqvist J.
Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase. J Med Chem. 2008 May 8;51(9):2648-56. Epub 2008 Apr 12.
Chen IJ, 2002
Chen IJ, Neamati N, MacKerell AD Jr.
Structure-based inhibitor design targeting HIV-1 integrase. Curr Drug Targets Infect Disord. 2002 Sep;2(3):217-34.
Cingolani A, 2002
Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A.
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002 Feb 15;16(3):369-79.
Clevenbergh P, 2000
Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P.
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther. 2000 Mar;5(1):65-70.
Cohen CJ, 2002
Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA3001 Study Team.
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002 Mar 8;16(4):579-88.
Coffin JM, 1995
Coffin JM.
HIV population dynamics in vivo : implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483-9.
Creagh T, 2001
Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, Flavin MT, Xu ZQ.
Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother. 2001 May;45(5):1379-86.
D
Daelemans D, 2007
Daelemans D, Lu R, De Clercq E, Engelman A.
Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. J Virol. 2007 Apr;81(8):4381-5. Epub 2007 Feb 7.
Das K, 2004
Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, de Béthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E.
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004 May 6;47(10):2550-60.
Dau B, 2009
Dau B, Holodniy M.
Novel targets for antiretroviral therapy: clinical progress to date. Drugs. 2009;69(1):31-50. doi: 10.2165/00003495-200969010-00003.
De Meyer S, 2005
De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Béthune MP.
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21.
Dierynck I, 2007
Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K.
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007 Dec;81(24):13845-51. Epub 2007 Oct 10.
Durant J, 1999
Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P.
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999 Jun 26;353(9171):2195-9.
E
Emmelkamp JM, 2007
Emmelkamp JM, Rockstroh JK.
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. Eur J Med Res. 2007 Oct 15;12(9):409-17.
Engelman A, 1991
Engelman A, Mizuuchi K, Craigie R.
HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell. 1991 Dec 20;67(6):1211-21.
G
Garvey L, 2009
Garvey L, Winston A.
Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs. 2009 Jul;18(7):1035-41.
Goebel F, 2006
Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B.
Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects. AIDS. 2006 Aug 22;20(13):1721-6.
Goodsell DS, 1996
Goodsell DS, Morris GM, Olson AJ.
Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit. 1996 Jan-Feb;9(1):1-5.
H
Harris KS, 2005
Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R.
KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005 Jul;67(1):1-9.
Haubrich RH, 2005
Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD; California Collaborative Treatment Group.
A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005 Feb 18;19(3):295-302.
Hazuda DJ, 2000
Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD.
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000 Jan 28;287(5453):646-50.
Hertogs K, 1998
Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R.
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998 Feb;42(2):269-76.
Hicks C, 2009
Hicks C, Gulick RM.
Raltegravir: the first HIV type 1 integrase inhibitor.
Clin Infect Dis. 2009 Apr 1;48(7):931-9. doi: 10.1086/597290.
Hightower KE, 2011
Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL 3rd, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR.
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9. doi: 10.1128/AAC.00157-11. Epub 2011 Aug 1.
Hurt CB, 2014
Hurt CB, Sebastian J, Hicks CB, Eron JJ.
Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.
Clin Infect Dis. 2014 Feb;58(3):423-31. doi: 10.1093/cid/cit697. Epub 2013 Oct 21.
Hurwitz SJ, 2005
Hurwitz SJ, Otto MJ, Schinazi RF.
Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans.
Antivir Chem Chemother. 2005;16(2):117-27.
I
Imamura S, 2006
Imamura S, Ichikawa T, Nishikawa Y, Kanzaki N, Takashima K, Niwa S, Iizawa Y, Baba M, Sugihara Y.
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. J Med Chem. 2006 May 4;49(9):2784-93.
J
Jalaie M, 2006
Jalaie M, Shanmugasundaram V.
Virtual screening: are we there yet? Mini Rev Med Chem. 2006 Oct;6(10):1159-67.
Japour AJ, 1995
Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR.
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis. 1995 May;171(5):1172-9.
Johnson VA, 2008
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.
Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med. 2008 Mar-Apr;16(1):62-8.
K
Kellam P, 1994
Kellam P, Larder BA.
Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1994 Jan;38(1):23-30.
Keseru GM, 2006
Keseru GM, Makara GM.
Hit discovery and hit-to-lead approaches. Drug Discov Today. 2006 Aug;11(15-16):741-8.
Kirkpatrick DL, 1999
Kirkpatrick DL, Watson S, Ulhaq S.
Structure-based drug design: combinatorial chemistry and molecular modeling. Comb Chem High Throughput Screen. 1999 Aug;2(4):211-21.
Klibanov OM. 2009
Klibanov OM.
Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs. 2009 Feb;10(2):190-200.
Koh Y, 2003
Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H.
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro . Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9.
L
Lalezari J, 2008
Lalezari J, Yadavalli GK, Para M, Richmond G, Dejesus E, Brown SJ, Cai W, Chen C, Zhong J, Novello LA, Lederman MM, Subramanian GM.
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis. 2008 Mar 1;197(5):721-7.
Lazzarin A, 2007
Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 7;370(9581):39-48.
M
Madruga JV, 2007
Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 7;370(9581):29-38.
Malet I, 2008
Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG.
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.
Markowitz M, 2006
Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H.
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15.
Marrone TJ, 1997
Marrone TJ, Briggs JM, McCammon JA.
Structure-based drug design: computational advances. Annu Rev Pharmacol Toxicol. 1997;37:71-90.
Martin DE, 2008
Martin DE, Salzwedel K, Allaway GP.
Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
Meynard JL, 2002
Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group.
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002 Mar 29;16(5):727-36.
N
Narayanasamy J, 2007
Narayanasamy J, Pullagurla MR, Sharon A, Wang J, Schinazi RF, Chu CK.
Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. Antiviral Res. 2007 Sep;75(3):198-209. Epub 2007 Mar 30.
Nitanda T 2005
Nitanda T, Wang X, Kumamoto H, Haraguchi K, Tanaka H, Cheng YC, Baba M.
Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro. Antimicrob Agents Chemother. 2005 Aug;49(8):3355-60.
O
Olson AJ, 1998
Olson AJ, Goodsell DS.
Automated docking and the search for HIV protease inhibitors. SAR QSAR Environ Res. 1998;8(3-4):273-85.
P
Paterson DL, 2000
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N.
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21-30.
Pett SL, 2009
Pett SL, McCarthy MC, Cooper DA, MacRae K, Tendolkar A, Norris R, Strizki JM, Williams KM, Emery S.
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients. Antivir Ther. 2009;14(1):111-5.
Petropoulos CJ, 2000
Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM.
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Apr;44(4):920-8.
Posner BA, 2005
Posner BA.
High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. Curr Opin Drug Discov Devel. 2005 Jul;8(4):487-94.
R
Ramanathan S, 2007
Ramanathan S, Shen G, Cheng A, Kearney BP.
Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):274-9.
Ray AS, 2007
Ray AS, Vela JE, Boojamra CG, Zhang L, Hui H, Callebaut C, Stray K, Lin KY, Gao Y, Mackman RL, Cihlar T.
Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrob Agents Chemother. 2008 Feb;52(2):648-54. Epub 2007 Dec 3.
S
Seki T, 2015
Seki T, Suyama-Kagitani A, Kawauchi-Miki S, Miki S, Wakasa-Morimoto C, Akihisa E, Nakahara K, Kobayashi M, Underwood MR, Sato A, Fujiwara T, Yoshinaga T.
Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
Antimicrob Agents Chemother. 2015 May;59(5):2596-606. doi: 10.1128/AAC.04844-14. Epub 2015 Feb 17.
Shimura K, 2008
Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M.
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. Epub 2007 Oct 31.
Stone ND, 2007
Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, MacFarland RT, Park JG, Lalama C, Snyder S, Kallungal B, Klingman KL, Hendrix CW.
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother. 2007 Jul;51(7):2351-8. Epub 2007 Apr 23. Erratum in: Antimicrob Agents Chemother. 2007 Aug;51(8):3047.
Sweeney ZK, 2008
Sweeney ZK, Klumpp K.
Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr Opin Drug Discov Devel. 2008 Jul;11(4):458-70.
T
TMC125-C223 Writing Group, 2007
TMC125-C223 Writing Group, Nadler JP, Berger DS, Blick G, Cimoch PJ, Cohen CJ, Greenberg RN, Hicks CB, Hoetelmans RM, Iveson KJ, Jayaweera DS, Mills AM, Peeters MP, Ruane PJ, Shalit P, Schrader SR, Smith SM, Steinhart CR, Thompson M, Vingerhoets JH, Voorspoels E, Ward D, Woodfall B.
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007 Mar 30;21(6):F1-10.
Tural C, 2002
Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, Domingo P, Boucher C, Rey-Joly C, Clotet B; Havana Study Group.
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002 Jan 25;16(2):209-18.
V
Verkhivker G, 2008
Verkhivker G, Tiana G, Camilloni C, Provasi D, Broglia RA.
Atomistic simulations of the HIV-1 protease folding inhibition. Biophys J. 2008 Jul;95(2):550-62. Epub 2008 Mar 28.
W
Wainberg MA, 2015
Wainberg MA, Han YS.
HIV-1 resistance to dolutegravir: update and new insights.
J Virus Erad. 2015 Jan 1;1(1):13-6.
Y
Yoshida S, 2015
Yoshida S1, Hattori J, Matsuda M, Okada K, Kazuyama Y, Hashimoto O, Ibe S, Fujisawa S, Chiba H, Tatsumi M, Kato S, Sugiura W.
Japanese external quality assessment program to standardize HIV-1 drug-resistance testing AIDS Res Hum Retroviruses. 2015 Mar;31(3):318-25. doi: 10.1089/aid.2014.0059. Epub 2014 Dec 3.
Z
Zolopa AR, 1999
Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B.
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999 Dec 7;131(11):813-21.
[No authors listed], 2008
[No authors listed]
SP-01A helps with quality of life.
AIDS Patient Care STDS. 2008 Feb;22(2):160-1.
[No authors listed] 2007
[No authors listed]
Anti-HIV agents. Another receptor blocker--INCB9471. TreatmentUpdate. 2007 Sep-Oct;19(6):6-7.
[No authors listed] 2008
[No authors listed]
Phase III trial begins for elvitegravir. AIDS Patient Care STDS. 2008 Sep;22(9):762-3.
